<SEC-DOCUMENT>0001140361-26-001727.txt : 20260121
<SEC-HEADER>0001140361-26-001727.hdr.sgml : 20260121
<ACCEPTANCE-DATETIME>20260121060037
ACCESSION NUMBER:		0001140361-26-001727
CONFORMED SUBMISSION TYPE:	FWP
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20260121
DATE AS OF CHANGE:		20260121

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Anteris Technologies Global Corp.
		CENTRAL INDEX KEY:			0002011514
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-292565
		FILM NUMBER:		26544701

	BUSINESS ADDRESS:	
		STREET 1:		860 BLUE GENTIAN ROAD
		STREET 2:		SUITE 340
		CITY:			EAGAN
		STATE:			MN
		ZIP:			55121
		BUSINESS PHONE:		651-493-0606

	MAIL ADDRESS:	
		STREET 1:		860 BLUE GENTIAN ROAD
		STREET 2:		SUITE 340
		CITY:			EAGAN
		STATE:			MN
		ZIP:			55121

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Anteris Technologies Global Corp.
		CENTRAL INDEX KEY:			0002011514
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP

	BUSINESS ADDRESS:	
		STREET 1:		860 BLUE GENTIAN ROAD
		STREET 2:		SUITE 340
		CITY:			EAGAN
		STATE:			MN
		ZIP:			55121
		BUSINESS PHONE:		651-493-0606

	MAIL ADDRESS:	
		STREET 1:		860 BLUE GENTIAN ROAD
		STREET 2:		SUITE 340
		CITY:			EAGAN
		STATE:			MN
		ZIP:			55121
</SEC-HEADER>
<DOCUMENT>
<TYPE>FWP
<SEQUENCE>1
<FILENAME>ny20062007x5_fwp.htm
<DESCRIPTION>FWP
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 9pt; font-weight: bold;">Issuer Free Writing Prospectus</div>
    <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 9pt; font-weight: bold;">Filed Pursuant to Rule 433</div>
    <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 9pt; font-weight: bold;">Registration File No. 333-292565</div>
    <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 9pt; font-weight: bold;">Relating to the</div>
    <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 9pt; font-weight: bold;">Preliminary Prospectus Supplement</div>
    <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 9pt; font-weight: bold;">Dated January 20, 2026</div>
    <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 9pt; font-weight: bold;">(To Prospectus Dated January 8, 2026)</div>
    <div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering</div>
    </div>
    <div style="background-color: #FEFEFE;">
      <div><br>
      </div>
      <div style="text-align: justify; margin-top: 12pt;">January 20, 2026</div>
    </div>
    <div style="background-color: rgb(254, 254, 254);">
      <div><br>
      </div>
    </div>
    <div style="background-color: #FEFEFE;">
      <div style="text-align: justify; margin-bottom: 8pt;">MINNEAPOLIS and BRISBANE, Australia, January 20, 2026 (GLOBE NEWSWIRE)<font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;</font>-- <font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Anteris Technologies Global Corp.</font> (&#8220;<font style="background-color: rgb(255, 255, 255); font-family: 'Times New Roman',Times,serif; font-weight: bold;">Anteris&#8221;</font><font style="background-color: rgb(255, 255, 255); font-family: 'Times New Roman',Times,serif;">&#160;or the&#160;&#8220;</font><font style="background-color: rgb(255, 255, 255); font-family: 'Times New Roman',Times,serif; font-weight: bold;">Company&#8221;</font>) (<font style="background-color: rgb(255, 255, 255); font-family: 'Times New Roman',Times,serif;">NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function,</font>
        today announced the pricing of its public offering (the &#8220;Offering&#8221;) of 34,782,609 shares of its common stock (the &#8220;Shares&#8221;). The Shares are being sold at a public offering price of $5.75 per share. The gross proceeds to the Company from the
        Offering, prior to deducting underwriting discounts, commissions and estimated offering expenses, are expected to be approximately $200 million. The Offering is expected to close on January 22, 2026, subject to the satisfaction of customary closing
        conditions.</div>
      <div style="text-align: justify; margin-bottom: 8pt;">All Shares to be sold in the Offering are being sold by the Company. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 5,217,391 Shares from the
        Company at the public offering price, less underwriting discounts and commissions.</div>
      <div style="text-align: justify; margin-bottom: 8pt;">In addition, pursuant to a stock purchase agreement, dated January 20, 2026, Anteris has agreed to sell to Medtronic plc (through a wholly owned subsidiary) in a private placement exempt from the
        registration requirements of the Securities Act of 1933, as amended, and at a price per share equal to the public offering price in the Offering, up to $90.0 million of shares of common stock, subject to a minimum purchase of 16.0% of the number of
        shares of common stock outstanding after the Offering and a maximum purchase of 19.99% of the number of shares of common stock outstanding after the Offering (the &#8220;Private Placement&#8221;). Completion of the Private Placement is contingent on completion
        of the Offering; however, the Offering is not contingent on the completion of the Private Placement.</div>
      <div style="text-align: justify; margin-bottom: 8pt;">Anteris intends to use the net proceeds from the Offering, together with its existing cash and cash equivalents and the net proceeds from the Private Placement, to support the next stage of growth
        and advance execution of the Company&#8217;s clinical strategy. This includes ongoing recruitment and study execution of the DurAVR<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> Transcatheter Heart Valve (&#8220;DurAVR<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> THV&#8221;) global pivotal trial for patients with severe aortic stenosis (the &#8220;PARADIGM Trial&#8221;) and expansion of manufacturing capabilities. In addition, a portion of the
        proceeds is expected to fund ongoing research and development for v2vmedtech, inc., with the balance allocated to working capital and other general corporate purposes determined from time to time.</div>
      <div style="text-align: justify; margin-bottom: 8pt;">Barclays, Wells Fargo Securities and Cantor are acting as joint book-running managers for the Offering. Barrenjoey Markets Pty Limited is acting as financial advisor in connection with the
        Offering to investors in Asia-Pacific and certain other jurisdictions outside of the United States and Canada. Wells Fargo Securities is acting as sole placement agent in connection with the private placement of Anteris&#8217; shares to Medtronic.</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-bottom: 8pt;">The Shares are being offered by the Company pursuant to a shelf registration statement on Form S-3 (the &#8220;Form S-3 Registration Statement&#8221;) that was filed with the Securities and Exchange
        Commission (the &#8220;SEC&#8221;) and declared effective on January 8, 2026. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the Offering have been filed with the SEC and are available on the SEC&#8217;s
        website at <font style="font-family: 'Times New Roman',Times,serif;">www.sec.gov</font>. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the Offering may be obtained from: Barclays Capital Inc., c/o
        Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (888) 603-5847 or by e-mail at&#160;barclaysprospectus@broadridge.com; Wells Fargo Securities, LLC, 90 South 7th Street, Minneapolis, MN 55402, by telephone at
        (800) 645-3751 (option #5), or by email at WFScustomerservice@wellsfargo.com; or Cantor Fitzgerald &amp; Co., by mail at Attention: Capital Markets, 110 East 59th Street, New York, NY 10022, or by email at prospectus@cantor.com.</div>
      <div style="text-align: justify; margin-bottom: 8pt;">The shares of common stock offered and sold in the Private Placement have not been registered under the Securities Act or any state&#8217;s securities laws. Accordingly, such securities may not be
        offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. The prospectus supplement and the accompanying prospectus related to
        the Offering are not an offer to sell or a solicitation of an offer to buy any securities in connection with the Private Placement.</div>
      <div style="text-align: justify; margin-bottom: 8pt;">This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities, and shall not constitute an offer,
        solicitation or sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. As disclosed in the
        preliminary prospectus supplement related to the Offering, the underwriters may engage in stabilizing actions or related activities in connection with the Offering.</div>
      <div><br>
      </div>
    </div>
    <div style="background-color: #FEFEFE;">
      <div style="text-align: justify; margin-bottom: 6pt; font-weight: bold;">About Anteris</div>
      <div><br>
      </div>
    </div>
    <div>
      <div style="text-align: justify; margin-bottom: 7.5pt;">Anteris Technologies Global Corp. (NASDAQ: <font style="font-family: 'Times New Roman',Times,serif;">AVR</font>, ASX: AVR) is a global structural heart company committed to designing,
        developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary
        professionals delivering restorative solutions to structural heart disease patients.</div>
      <div style="margin: 0px 0px 0px; text-align: justify;">Anteris&#8217; lead product, the DurAVR<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174; </sup>THV, was designed in collaboration with the world&#8217;s leading interventional
        cardiologists and cardiac surgeons to treat aortic stenosis &#8211; a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174; </sup>THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174; </sup>THV is made using a single piece of molded ADAPT<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174; </sup>tissue, Anteris&#8217; patented anti-calcification tissue technology. ADAPT<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174; </sup>tissue, which is FDA-cleared, has been used clinically for over 10&#160;years and distributed for use in over 55,000 patients worldwide. The DurAVR<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>&#160;THV System is comprised of the DurAVR<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174; </sup>valve, the ADAPT<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>&#160;tissue, and the balloon-expandable ComASUR<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>&#160;Delivery System. The safety and efficacy of the DurAVR<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> THV are being evaluated in the PARADIGM Trial (NCT07194265), with the first patients enrolled and implanted with the DurAVR<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> THV in Denmark during the fourth quarter of 2025.</div>
      <div><br>
      </div>
    </div>
    <div style="background-color: #FEFEFE;">
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-bottom: 6pt; font-weight: bold;">Forward-Looking Statements</div>
      <div><br>
      </div>
    </div>
    <div style="background-color: #FEFEFE;">
      <div style="text-align: justify;">This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words &#8220;believe,&#8221;
        &#8220;project,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;budget,&#8221; &#8220;target,&#8221; &#8220;aim,&#8221; &#8220;strategy,&#8221; &#8220;plan,&#8221; &#8220;guidance,&#8221; &#8220;outlook,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;will be,&#8221; &#8220;will continue,&#8221; &#8220;will likely result&#8221; and similar expressions,
        although not all forward-looking statements contain these identifying words. Forward-looking statements include, but are not limited to, any statements regarding the Offering and the Private Placement, the anticipated use of the net proceeds of the
        Offering and the Private Placement, and that the underwriters may engage in stabilizing actions or related activities in connection with the Offering. These forward-looking statements are subject to a number of risks, uncertainties, and
        assumptions, including those described under &#8220;Risk Factors&#8221; in the Form S-3 Registration Statement and the preliminary prospectus supplement and accompanying prospectus related to the Offering. Readers are cautioned not to put undue reliance on
        forward-looking statements, and except as required by law, the Company does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.</div>
      <div><br>
      </div>
    </div>
    <div style="text-align: justify; margin-bottom: 6pt; font-weight: bold;">For more information:</div>
    <div style="text-align: justify; margin-bottom: 6pt; font-weight: bold;">
      <table id="z6946a7d0209346c3a528a2ab41d4a549" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%;"><font style="font-weight: bold;">Investor Relation</font></td>
            <td style="width: 50%;">
              <div style="margin: 0px 0px 0px; text-align: justify;"><font style="font-weight: bold;">Investor Relations (US)</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%;">investors@anteristech.com</td>
            <td style="width: 50%;">mchatterjee@bplifescience.com</td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%;">Debbie Ormsby<font style="display: inline-block; text-indent: 0px; width: 288pt;" class="TRGRRTFtoHTMLTab"> <br>
              </font></td>
            <td style="width: 50%;">Malini Chatterjee, Ph.D.</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 50%;">&#160;</td>
            <td rowspan="1" style="width: 50%;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 50%;">Anteris Technologies Global Corp.</td>
            <td rowspan="1" style="width: 50%;">Blueprint Life Science Group</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 50%;">&#160;</td>
            <td rowspan="1" style="width: 50%;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 50%;">+61 1300 550 310 | +61 7 3152 3200</td>
            <td rowspan="1" style="width: 50%;">+1 917 330 4269</td>
          </tr>

      </table>
    </div>
    <div style="text-align: justify; margin-bottom: 12pt;">
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"><font style="font-weight: bold;"></font></div>
    <div style="text-align: justify; margin-bottom: 12pt;"><font style="display: inline-block; text-indent: 0px; width: 396pt;" class="TRGRRTFtoHTMLTab"></font><br>
    </div>
    <div style="text-align: justify; margin-bottom: 12pt;"><font style="display: inline-block; text-indent: 0px; width: 288pt;" class="TRGRRTFtoHTMLTab"></font><br>
    </div>
    <div style="text-align: justify; margin-bottom: 12pt;"><br>
    </div>
    <div style="text-align: justify; margin-bottom: 12pt;"><br>
    </div>
    <div style="background-color: rgb(254, 254, 254);">
      <div><br>
      </div>
    </div>
    <div>
      <div><br>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
